Alentis Appoints Alberto Toso Chief Scientific Officer

BASEL, Switzerland, April 29, 2024--Alentis Therapeutics ("Alentis"), a clinical-stage biotechnology company developing treatments for organ fibrosis and Claudin-1 positive tumors, announced today that Dr. Alberto Toso has been appointed as Chief Scientific Officer effective immediately. Alberto joined Alentis in 2021 as Head of Oncology.

Related Keywords

France ,Bellinzona ,Ticino ,Switzerland ,Zurich ,Züsz ,French ,Thomas Baumert ,Sariette Witte ,Alberto Toso ,Roberto Iacone ,Opatrick Wilson ,French National Institute Of Health ,Research Inserm ,Nature Communications ,University Of Strasbourg ,Department Head ,Institute Of Oncology Research In Bellinzona ,Alentis Therapeutics ,Chief Scientific Officer ,Chief Executive Officer ,Oncology Research ,French National Institute ,Medical Research ,